Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States:: Results from the TRUST Surveillance Program (1998-2002)

被引:137
作者
Karlowsky, JA
Thornsberry, C
Jones, ME
Evangelista, AT
Critchley, IA
Sahm, DF
机构
[1] Focus Technol, Herndon, VA 20171 USA
[2] Focus Technol, Franklin, TN USA
[3] Focus Technol, Hilversum, Netherlands
[4] Ortho McNeil Pharmaceut, Raritan, NJ USA
关键词
D O I
10.1086/374052
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To identify factors associated with antimicrobial resistance, data were analyzed from 27,828 isolates of Streptococcus pneumoniae submitted to the Tracking Resistance in the United States Today ( TRUST) surveillance program during 4 consecutive respiratory seasons. From the 1998-1999 season to the 2001-2002 season, the prevalence of azithromycin resistance increased by 4.8% to 27.5%, the prevalence of penicillin resistance increased by 3.7% to 18.4%, the prevalence of ceftriaxone resistance increased by 0.5% to 1.7%, and the prevalence of levofloxacin resistance increased by 0.3% to 0.9%. Isolates recovered from patients <18 years of age and lower respiratory tract specimens had elevated rates of penicillin, azithromycin, and trimethoprimsulfamethoxazole resistance (P<.00001); penicillin resistance correlated with coresistance to trimethoprimsulfamethoxazole (87.3%), azithromycin (76.3%), ceftriaxone ( 9.1%), and levofloxacin (1.3%) (P<.00001). Only 62 (0.2%) of 27,828 isolates were concurrently resistant to penicillin and levofloxacin. Minimum inhibitory concentrations (MICs) of penicillin correlated strongly with MICs of ceftriaxone (R-2=0.90), trimethoprimsulfamethoxazole (R-2=0.53), and azithromycin (R-2=0.41). Patient age, specimen source, and penicillin resistance were factors associated with antimicrobial resistance, particularly for nonfluoroquinolone antimicrobial agents.
引用
收藏
页码:963 / 970
页数:8
相关论文
共 29 条
[21]  
Peterson DE, 1999, NEW ENGL J MED, V341, P1547
[22]   Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States:: 2-year longitudinal analysis [J].
Sahm, DF ;
Karlowsky, JA ;
Kelly, LJ ;
Critchley, IA ;
Jones, ME ;
Thornsberry, C ;
Mauriz, Y ;
Kahn, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1037-1042
[23]   Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States [J].
Sahm, DF ;
Peterson, DE ;
Critchley, IA ;
Thornsberry, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) :2521-2524
[24]   Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998 [J].
Thornsberry, C ;
Jones, ME ;
Hickey, ML ;
Mauriz, Y ;
Kahn, J ;
Sahm, DF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) :749-759
[25]   Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States:: Results from the TRUST Surveillance Program, 1999-2000 [J].
Thornsberry, C ;
Sahm, DF ;
Kelly, LJ ;
Critchley, IA ;
Jones, ME ;
Evangelista, AT ;
Karlowsky, JA .
CLINICAL INFECTIOUS DISEASES, 2002, 34 :S4-S16
[26]   Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents:: a prospective US study [J].
Thornsberry, C ;
Ogilvie, PT ;
Holley, HP ;
Sahm, DF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2612-2623
[27]   Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. [J].
Whitney, CG ;
Farley, MM ;
Hadler, J ;
Harrison, LH ;
Lexau, C ;
Reingold, A ;
Lefkowitz, L ;
Cieslak, PR ;
Cetron, M ;
Zell, ER ;
Jorgensen, JH ;
Schuchat, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1917-1924
[28]   In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae [J].
Zhanel, GG ;
Walters, M ;
Laing, N ;
Hoban, DJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (04) :435-440
[29]  
2001, MMWR MORB MORTAL WKL, V5, P800